Evidence map›Paper›PMID 42729307›Full record

ReviewFrontiers in endocrinology2026

Novel compound heterozygous

Wenting Zhang, Junfeng Zeng, Yanjin Li, Cailian Xie, Zhihao Sun, Guizhen Lyu, Tizhen Yan, Xiaoling Huang

Abstract readCase ReportsReview
In one paragraph

Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wenting ZhangNeonatal Disease Screening Center, Dongguan Maternal and Child Health Care Hospital, Dongguan, Guangdong, China.
Junfeng ZengNeonatal Disease Screening Center, Dongguan Maternal and Child Health Care Hospital, Dongguan, Guangdong, China.
Yanjin LiNeonatal Disease Screening Center, Dongguan Maternal and Child Health Care Hospital, Dongguan, Guangdong, China.
Cailian XieNeonatal Disease Screening Center, Dongguan Maternal and Child Health Care Hospital, Dongguan, Guangdong, China.
Zhihao SunNeonatal Disease Screening Center, Dongguan Maternal and Child Health Care Hospital, Dongguan, Guangdong, China.
Guizhen LyuDongguan Molecular Diagnostic Technology and Infectious Disease Medical Test Engineering Research Center, Dongguan Labway Clinical Laboratory Co., Ltd., Dongguan, Guangdong, China.
Tizhen YanCentral Laboratory, Dongguan Maternal and Child Health Care Hospital, Dongguan, China.
Xiaoling HuangNeonatal Disease Screening Center, Dongguan Maternal and Child Health Care Hospital, Dongguan, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cytochrome P450 oxidoreductase deficiency (PORD) is an ultra-rare autosomal recessive disorder within the congenital adrenal hyperplasia (CAH) spectrum, characterized by a broad clinical spectrum involving steroidogenesis defects, genital anomalies, and skeletal abnormalities. Case presentation: We report a phenotypically female neonate with a 46,XY karyotype whose postnatal diagnostic evaluation was initiated after newborn screening revealed elevated 17-hydroxyprogesterone (17-OHP) concentration. The patient presented with mild hypertelorism, mild nasal hypoplasia, and low-set bilateral ears, along with female external genitalia consistent with disorder of sex development (DSD) and anal atresia. Radiological evaluation revealed femoral bowing and subsequent fracture. The craniofacial and skeletal abnormalities were consistent with the features of Antley-Bixler syndrome (ABS). Endocrine evaluation revealed elevated progesterone, markedly reduced testosterone, and secondary hyperaldosteronism. Genetic analysis identified three novel variants in the Conclusions: This study describes a neonate with PORD caused by three novel POR variants and expands the known clinical spectrum of PORD by identifying rare manifestations including anal atresia and hearing loss. RNA-seq provided valuable functional evidence for variant interpretation and facilitated accurate molecular diagnosis. These findings highlight the importance of integrating genetic phasing, transcript-level functional analysis, and comprehensive clinical evaluation for precise diagnosis and counseling in rare endocrine disorders.

Indexed as

Antley-Bixler Syndrome PhenotypeDisorder of Sex Development, 46,XYMutationCytochrome P-450 Enzyme SystemFemaleHeterozygoteHumansInfant, NewbornCytochrome P-450 Enzyme SystemPOR protein, humanAntley-Bixler syndromecongenital adrenal hyperplasiacytochrome P450 reductase deficiencydisorder of sex developmentPOR gene

Identifiers

PMID42729307
PMCPMC13561933

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.